Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds

Research in Virology

Volumn 148, Issue 5, 1997, Pages 353-365

  Crance, J M ^a   Gratier, D ^a   Guimet, J ^a   Jouan, A ^a  

^a CENTRE DE RECHERCHES   (France)

Author keywords

Antiviral agents; Bunyaviridae; Inhibition; Phlebovirus; Replication; Sandfly fever virus; Sicilian virus

Indexed keywords

3 DEAZAURIDINE; ACICLOVIR; AMANTADINE; ANTIVIRUS AGENT; AZAURIDINE; CARRAGEENAN; CHLOROQUINE; COLCHICINE; CYTOCHALASIN B; CYTOCHALASIN D; DANSYLCADAVERINE; DEXTRAN SULFATE; DIPYRIDAMOLE; ERBSTATIN; FORMYCIN B; FUCOIDIN; GENISTEIN; GLUCOSAMINE; GLYCYRRHIZIC ACID; GUANIDINE; MONENSIN; NEOMYCIN; NIGERICIN; PENTOSAN POLYSULFATE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; SURAMIN; UNINDEXED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BUNYAVIRUS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALIA; BUNYAVIRIDAE; ORTHOBUNYAVIRUS; PHLEBOVIRUS; SANDFLY FEVER SICILIAN VIRUS;

EID: 0030717662     PISSN: 09232516     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2516(97)89132-7     Document Type: Article

References (40)

1. Baba, M., Snoeck, R., Pauwels, R. & De Clercq (1988), Sulphated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and immunodeficiency virus. Antimicrob. Agents Chemother., 32, 1742-1745.
2. Balducci, M., Fausto, A.M. & Verani, P. (1985), Phlebotomus-transmitted viruses in Europe, in "Proceedings of the International Congress for Infectious Diseases" (101-104). Edizion Luigi Pozzi, Rome.
3. Bartelloni, P.J. & Tesh, R.B. (1976), Clinical and serological responses of volunteers infected with phlebotomus fever virus (Sicilian type). Am. J. Trop. Med. Hyg., 25, 456-462.
4. Crance, J.M., Biziagos, E., Passagot, J., Van Cuyck-Gandré, H. & Deloince, R. (1990), Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J. Med. Virol., 31, 155-160.
5. Crance, J.M., Lévêque, F., Biziagos, E., Van Cuyck-Gandré, H., Jouan, A. & Deloince, R. (1994), Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res., 23, 63-76.
6. Crance, J.M., Lévêque, F., Chousterman, S., Jouan, A., Trépo, C. & Deloince, R. (1995), Antiviral activity of recombinant interferon-α on hepatitis A virus replication in human liver cells. Antiviral Res., 28, 69-80.
7. De Clercq, E. (1987), Suramin in the treatment of AIDS: mechanism of action. Antiviral Res., 7, 1-10.
8. De Somer, P., De Clercq, E., Billiau, A., Schonne, E. & Claesen, M. (1968), Antiviral activity of polyacrylic acid and polymethacrylic acid-I. mode of action in vitro. J. Virol., 2, 878-885.
9. Deneau, D.G. & Farber, E.M. (1975), The treatment of psoriasis with azaribine. Dermatologica, 151, 158-163.
10. Einsenberger, M.A., Sinibaldi, V.J., Reyno, L.M., Sridhara, R., Jodrell, D.I., Zuhowski, E.G., Tkaczuk, K.H., Lowit, M.H., Hemady, R.K. & Jacobs, S.C. (1995), Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancers. J. Clin. Oncol., 13, 2174-2186.
11. Finter, N.B., Chapman, S., Dowd, P., Johnston, J.M., Manna, V., Sarantis, N., Sheron, N., Scott, G., Phua, S. & Tatum, P.B. (1991), The use of interferon-α in virus infections. Drug, 42, 749-765.
12. Fried, M.W. (1996), Therapy of chronic viral hepatitis. Med. Clin. North Am., 80, 957-972.
13. Gonzalez-Scarano, F. & Nathanson, N. (1990), Bunyaviruses, in "Virology" (B.N. Fields, D.M. Knipe, R.M. Chanock, M.S. Hirsh, J.L. Melnick, T.P. Monath, B. Roiszman) (pp 1195-1228). Raven Press, New York.
14. Goswami, B.B., Borek, E. & Sharma, O.K. (1979), The broad spectrum agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun., 89, 830-836.
15. Hall, C.B., McBride, J.T., Walsh, E.E., Bell, D.M., Gala, C.L., Hildreth, S., Ten Heyck L.G. & Hall, W.J. (1983), Aerosolized ribavirin treatment of infants with respiratory syncitial viral infection. A randomized double-blind study. N. Engl. J. Med., 308, 1443-1447.
16. Hattori, T., Ikematsu, S., Koito, A., Matsushita, S., Maeda, Y., Hada, M., Fujimaki, M. & Takatsuki, K. (1989), Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS. Antiviral Res., 11, 255-262.
17. Hawking, F. (1978), Suramin: with special reference to onchocerciasis. Adv. Pharmacol. Chemother., 15, 289-322.
18. Hayden, F.G., Douglas, R.G. & Simons, R. (1980), Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob. Agents Chemother., 18, 536-541.
19. Hertig, M., Sabin, A.B. (1964), Sandfly fever (papataci, phlebotumus, three-day fever), in "Preventive Medicine in World War II, Vol. 7 Communicable Diseases" (109-174) (E.C. Hoff). Office of the Surgeon General, US Dept. of the Army, Washington.
20. Huggins, J.W., Kim, G.R., Brand, O.M. & McKee, K.T. (1986), Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis., 153, 489-497.
21. Huggins, J.W (1989), Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis., 11, 750-761.
22. Ito, M., Nakashima, H., Baba, M., Pauwels, R., De Clercq, E., Shigeta, S. & Yamamoto, N. (1987), Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity on the human immunodeficiency virus (HIV-HTLV-III/LAV). Antiviral Res., 7, 127-137.
23. Jouan, A., Le Gueno, B., Digoutte, J.P.; Philippe, B., Riou, O. & Adams, F. (1988), An RVF epidemic in southern Mauritania. Ann. Inst. Pasteur/Virol., 139, 307-308.
24. Lee, H.W. (1982), Korean hemorrhagic fever. Prog. Med. Virol., 28, 96-113.
25. Meegan, J.M. (1981), Rift Valley fever in Egypt: an overview of the epizootics in 1977 and 1978. Contr. Epidemiol. Biostat., 3, 100-113.
26. Morill, J.C., Jennings, G.B., Cosgriff, T.M., Gibbs, P.H. & Peters, C.J. (1989), Prevention of Rift Valley fever in rhesus monkeys with interferon-α. Rev. Infect. Dis., 11, S815-S825.
27. Numazaki, K. & Chiba, S. (1993), Natural course and trial of treatment for infantile liver dysfunction associated with cytomegalovirus infections. In Vivo, 7, 477-480.
28. Oldfield, E.C., Wallace, M.R., Hyams, K.C., Yousifi, A.A., Lewis, D.E. & Bourgeois A.L. (1991), Endemic infectious diseases of the Middle East. Rev. Inf. Dis., 1991, 13 (suppl. 3), S199-S217.
29. Peters, C.J., Reynolds, J.A., Slone, T.W., Jones, D.E. & Stephen, E.L. (1986), Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activitor. Antiviral Res., 6, 285-297.
30. Pompei, R., Flore, O., Marccialis, M.A., Pani, A. & Lodo, B. (1979), Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature (Lond.), 281, 689-690.
31. Rada, B. & Dragun, M. (1977), Antiviral action and selectivity of 6-azauridine. Ann. NY. Acad. Sc., 284, 410-417.
32. Reed, L.J. & Muench, H. (1938), A simple method of estimating fifty per cent end points. Amer. J. Hyg., 21, 493-497.
33. Sabin, A.B. (1948), Phlebotumus fever, in "Viral and rickettsial infections of man" (T.M. Rivers) (pp. 363-370). Lippincott, Philadelphia.
34. Sabin, A.B. (1951), Experimental studies on Phlebotomus (Pappataci, Sandfly) fever. A disease of military importance. Summary of existing knowledge and preliminary report of original investigations. J. Am. Med. Assoc., 125, 693-699.
35. Sidwell, R.W., Huffman, J.H., Barnett, B.B., Pifat, D.Y. (1988), In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob. Agents Chemother., 32, 331-336.
36. Sidwell, R.W., Huffman, J.H., Barnard, D.L., Smee, D.F., Warren, R.P., Chirigos, M.A., Kende, M. & Huggins, J. (1994), Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Res., 25, 105-122.
37. Stephen, E.L., Jones, D.E., Peters, C.J., Eddy, G.A., Loinzaux, P.S., Jahrling, P.B. (1980), Ribavirin treatment of toga-, arena- and bunyavirus infections in subhuman primates and other laboratory animal species, in: "Ribavirin: a broad spectrum antiviral agent", (169-183) (Smith, R.A., Kirkpatrick, W.). Academic Press, New York.
38. Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., Robins R.K. & Simon, L.N. (1973), Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA, 70, 1174-1178.
39. Witvrouw, M., Desmyter J. & De Clercq, E. (1994), Antiviral portrait series. - 4. Polysulphates as inhibitors of HIV and other enveloped viruses. Antiviral Chem. Chemother., 5, 345-359.
40. Wray, S.K., Gilbert, B.E. & Knight, V. (1985), Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res., 5, 39-48.